Sie sind auf Seite 1von 8

Questionnaire for Study on Impact of FTA on Domestic Pharma Industry

A.

Economic

Q.1

In your view, do exports of drugs offer a major growth opportunity for Indian drug
manufacturing companies?

Q.2

Your plans for expansion of your presence in the global market for the next three
years?

Q.3

How do you foresee FTAs being beneficial or detrimental to the domestic pharma
industry? Please elaborate the basis of your views?

Q.4

Which specific pharma products are, in your view, presently facing unhealthy
competition?

Q.5

In your opinion, will FTAs provide a fillip to research & development in


pharmaceuticals in the country.

Q.6

Will FTAs in pharmaceuticals lead to attracting MNCs to shift their research


activities to India?

Q.7

What tax benefits can the Govt. of India provide to facilitate R&D in India?

Q.8

What would be the overall impact of FTAs on exports of pharmaceuticals products


covered under the Indian System of Medicine?

Q.9

Does the existing Govt. policy on Drug Pricing support the domestic pharma
industry? Please elaborate your view.

Q.10

Your suggestions for combating the menace of spurious drugs?

B.

Technical

Q.1

Please list the names of the drugs and formulations manufactured at your plant.

Q.2

Please furnish the annual production of each of the above mentioned drugs for the
years 2003-04, 2004-05 and 2005-06 as per Proforma-T1.

Q.3

Please furnish the standard and actual raw materials, chemicals and intermediates
consumption per kg of production, in respect of each of the drugs mentioned above,
for the years 2003-04, 2004-05 and 2005-06 as per Proforma-T2.

Q.4

Please comment whether any of the input raw materials, chemicals and
intermediates used in the manufacture of above drugs are imported. If yes, then
please mention the reasons (like non-availability of indigenous materials, quality,
price differential, etc.) for necessitating imports.
Proforma-T1
Annual Production of Drugs
(in quantitative terms)

S.No.
1.

Name of Drug

HS Code

Unit

Annual Production
2003-04 2004-05 2005-06

(pl.specify)

2.
3.
4.
.
.
.
.
.
.
.
.
.
.
Proforma-T2
Standard and Actual Raw Materials Consumption per kg of Production of the Drug
(separately for each of the drugs)

Name of Name of the HS


the Drug Raw
Code
materials/che
micals/interm
ediates

Whether
Unit
rawmaterials/ch
emicals are
imported or
indigenous

Standard
Consumptio
n per kg of
production
of the drug

Actual consumption
per
kg
of
production of the
drug
2003
-04

(1) ..
(pl.
specify)

(2) ..
(pl.
specify)

(3) ..

(4) ..

1 pl. specify
2
3
.
.
.
1 pl. specify
2
3
.
.
.
1 pl. specify
2
3
.
.
.
.
.
.
.
.

2004
-05

2005
-06

C. Costing

1.

Companys audited Balance Sheet and Profit & Loss for the year 2003-04, 2004-05 and
2005-06 may please be furnished.

2.

An elaborate statement regarding impact of Free Trade Agreements (FTA) entered into
by India with countries such as Sri Lanka, Thailand, Singapore etc. on the financial
performance of your company. The impact so assessed, whether positive or negative,
may be analysed with respect to respective countries in a product-specific manner.

3.

In what way the company has been benefited by way of those FTAs especially in
reduction in cost of production due to low cost of imported inputs, if any. This may be
supported with product-wise detailed facts and figures.

4.

Significant increase, if any, both in terms of quantity and value, in the export of
products, separately for bulk drug and formulations to the FTA countries after the date
of signing those agreements. The reasons attributed to such increased export may be
further elaborated.

5.

Whether the company perceive any threat to its operations in financial terms, in respect
of any of its products due to the FTAs already signed and those expected to be signed
with other countries.

6.

Any other submission on costing and financial aspects the company wishes to make in
favour of or against FTAs.

*************

No. 3/23/2005-TC
Government of India
Ministry of Commerce & Industry
Department of IP&P
Tariff Commission
7th Floor, Lok Nayak Bhawan,
Khan Market, New Delhi.
Dated:

Feb15, 2007

To,
Subject:- Study on impact of FTAs on Indian Pharma Industry.
*****
Sir,
The Department of Chemicals and Petrochemicals have entrusted Tariff Commission to
conduct a study on the Impact of Free Trade Agreements on Domestic Pharma Industry. In this
context, the Tariff Commission has devised a Questionnaire (copy enclosed). I may mention that
your name has been provided by Indian Drug Manufacturers Association for the purpose of
collection of data. You are requested to furnish the information by e-mail in the prescribed form to
the undersigned on seema.gaur2@gmail.com on priority basis and latest by March 12, 2007.
Thanking you,

Yours faithfully,

( Seema Gaur )
Adviser & Study Coordinator

1.

Mr. Sudhir Kaval,


Medisynth Chemicals Pvt. Ltd,.
medisynth@vsnl.com

2.

Mr. S.R. Banatwala,


Meridian Enterprises Pvt. Ltd.,
office@meridianentp.com

3.

Mr. B.H. Patel,


Morvel Labs (P) Ltd.,
morvellab@sify.com

4.

Mr. Moham Motawani,


Megha Labs Pvt. Ltd.,
meghahealthcare@hotmail.com

5.

Mr. M.H. Mehta,


Mehtachem Industries,
info@mehtaherbals.com

6.

Dr. V. Chandrashekhar,
Kores (India) Ltd.,
koresed@vsnl.com

7.

Mr. H.H. Pandit,


M.J. Biopharm Pvt. Ltd.,
migroup@mi-india.com

8.

Dr. D. Patel,
Themis Laboratories Limited,
dineshpatel@themismedicare.com

9.

Mr. U.M. Deshpande,


Milan Laboratories India,
mllabs@vsnl.com

10.

Mr. K.R. Patel,


Troikaa Pharmaceuticals Ltd.,
troika@troikaapharma.com

11.

Mr. R.G. Mehta,


ICPA Health Products Ltd.,
icpahealth@eth.net

12.

Mr. R.C. Bora,


Twilight LI-Taka Pharma,

nrb@litaka.com
13.

Mr. A. Thacker,
Flamingo Pharmaceuticals Ltd.,
ashf@giasbm01.vsnl.net.in

14.

Mr. N. Kashyap,
Indchemie Health Specialities Pvt. Ltd.,
indchemie@vsnl.com

15.

Mr. Abhay Kanoria,


Anglo French Drugs & Indls. Ltd.,
angfreil@blr.vsnl.net.in

16.

Mr. C.D. Bendre,


Meyer Organics Pvt. Ltd.,
info@meyerorganics.com

17.

Mr. D.S. Coulagi,


Sigma Laboratories Ltd.,
sigmalab@vsnl.com

18.

Mr. B. Chudgar,
Intas Pharmaceuticals Ltd.,
intas@ad1.vsnl.net.in

19.

Mr. Shirish Dabir,


Emcure Pharmaceuticals Ltd.,
corporate@emcure.co.in

20.

Dr. R. Agarwal,
Macleods Pharmaceuticals Ltd.,
macleods@vsnl.com

21.

Mr. Darshan Patel,


Paras Pharmaceuticals Ltd.,
admin@paraspharma.com

22.

Mr. S.G. Kare,


Indoco Remedies Ltd.,
sgk@indoco.com

23.

Mr. Arvind Kumar B. Shah,


Arvind Remedies Ltd.,
arvindrem@eth.net

24.

Mr. P.R. Sonawala,


Ajanta Pharma Ltd.,
prabhakars@ajantapharma.com

25.

Mr. N.H. Israni,


Blue Cross Laboratories Ltd.,
nhi@bluecrosslabs.com

26.

Mr. D.M. Parekh,


Zandu Pharmaceuticals Works Ltd.,
info@bluecrosslabs.com

27.

Mr. Lalit Mittal,


Parental Drugs (India) Ltd.,
adidavid@cal.vsnl.net.in

28.

Dr. Kiran Mazumdar Shaw,


Biocon Ltd.,
tara.jayaram@bioconindia.com

29.

Mr. K. Anji Reddy,


Dr. Reddys Laboratories Ltd.,
drl@hd1.vsnl.net.in

30.

Dr. I.S. Gandhi,


Aurobindo Pharma Ltd.,
info@aurobindo.com

31.

Mr. S. Kanan,
Lupin Ltd.,
dbgupta@lupinpharma.com

32.

Mr. P.R. Patel,


Cadila Healthcare Ltd.,
pankaj@zyduscadila.com

33.

Mr. Dilip Shanghvi,


Sun Pharmaceutical Industries Ltd.,
dshanghvi@sunpharma.com